The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomized controlled trials.

• Exemestane administration significantly increased LDL-C. • Exemestane administration significantly decreased HDL-C and TC. • Exemestane prescription only lowered TG concentrations when it was administered for < 12 months. Postmenopausal women are prone to develop cardiovascular disorders. In addition, cardiovascular risk in women can be influenced by the long-term prescription of drugs that lead to estrogen deprivation, e.g., aromatase inhibitors, and that can cause dyslipidemia. Little is known about the impact of exemestane, an aromatase inhibitor, on serum lipids' concentration in women. Hence, we conducted a meta -analysis of randomized controlled trials (RCTs) to assess the influence of this pharmacological agent on the lipid profile in women. The Scopus, Web of Science, PubMed/Medline and EMBASE databases were searched by two surveyors for manuscripts published from the inception of these databases until April 3rd, 2023. No language restrictions were applied to the search. The random effects model was used to generate the combined results as weighted mean difference (WMD) and 95% confidence interval (CI). In total, 8 eligible RCTs were included in the meta -analysis. Overall results from the random effects model indicate that exemestane administration increases LDL-C (WMD: 4.42 mg/dL, 95 % CI: 0.44, 8.41, P = 0.02) and decreases HDL-C (WMD: −6.03 mg/dL, 95 % CI: −7.77, −4.29, P < 0.001) and TC (WMD: −5.40 mg/dL, 95 % CI: −9.95, −0.86, P = 0.02) levels, respectively. Moreover, exemestane prescription only lowered TG concentrations when it was administered for < 12 months (WMD: −14.60 mg/dL, 95 % CI: –23.57 to −5.62, P = 0.001). Currently available evidence suggests that the administration of exemestane in females increases LDL-C values and reduces HDL-C, TC, and, when prescribed for less than 12 months, TG concentrations. [ABSTRACT FROM AUTHOR]